Adil Daud, MD

Adil Daud, MD, a clinical professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco and director of Melanoma Clinical Research at the UCSF Helen Diller Family Comprehensive Cancer Center, compares the roles of immunotherapy versus dabrafenib (Tafinlar) plus trametinib (Mekinist) targeted therapy combinations in patients with advanced melanoma. The latter combination is appropriate and even preventative in select patients, but the decision between checkpoint immune therapy and immunotherapy comes down to what is best for each patient.

There are pros and cons to either treatment, says Daud. On one hand, patients can receive an oral treatment with a greater incidence of adverse events (AEs) that are more reversible. However, patients also have access to a treatment with a lower incidence of AEs that may be long-lasting and irreversible.

Videos

Adil Daud, MD, compares the roles of immunotherapy versus dabrafenib plus trametinib targeted therapy combinations in patients with advanced melanoma. The latter combination is appropriate and even preventative in select patients, but the decision between checkpoint immune therapy and immunotherapy comes down to what is best for each patient.

Immunotherapy Versus Targeted Therapy for Advanced Melanoma

Adil Daud, MD, clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses challenges facing the field of melanoma.

Challenges Facing the Field of Melanoma

Adil Daud, MD, clinical professor, medicine, dermatology, University of California, San Francisco, discusses the challenges of treating patients with metastatic melanoma with BRAF inhibitor monotherapy.

At the Society for Melanoma Research 2013 Congress, Daud presented an overall survival update for BRF113220 part C, a phase II three-arm randomized study of dabrafenib alone versus combination of dabrafenib and trametinib in patients with BRAF V600 mutation-positive metastatic melanoma.

Read about the treatment of melanoma with

Adil Daud, MD | Authors

Articles

Immunotherapy Versus Targeted Therapy for Advanced Melanoma

Challenges Facing the Field of Melanoma

The Challenges of Treating Metastatic Melanoma With BRAF Inhibitor Monotherapy